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Abstract Cytochrome P450 2A6 (CYP2A6) is a polymorphic
enzyme responsible for the oxidation of certain precarcinogens
and drugs and is the major nicotine C-oxidase. The role of
CYP2A6 for nicotine elimination was emphasised recently by the
finding that smokers carrying defective CYP2A6 alleles
consumed fewer cigarettes [Pianezza et al. (1998) Nature 393,
750]. The method used for CYP2A6 genotyping has, however,
been found to give erroneous results with respect to the coumarin
hydroxylase phenotype, a probe reaction for the CYP2A6
enzyme. The present study describes an allele-specific PCR
genotyping method that identifies the major defective CYP2A6
allele and accurately predicts the phenotype. An allele frequency
of 1^3% was observed in Finnish, Spanish, and Swedish
populations, much lower than described previously.
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1. Introduction
Cytochromes P450 is a superfamily of haem thiolate en-
zymes involved in the metabolism of numerous endogenous
and exogenous compounds including steroid hormones, fatty
acids, precarcinogens, and a variety of clinically used drugs. A
pronounced interindividual variability in the expression of
drug-metabolising P450s exists because of genetic and envi-
ronmental factors. Based on the genetic variation, subjects are
classi¢ed into poor (PM), extensive (EM), or ultrarapid me-
tabolisers (UM) [1] and accordingly a pronounced interindi-
vidual di¡erence in the metabolism of and sensitivity to drugs
and other xenobiotics is seen [1,2]. PMs for CYP2D6 or
CYP2C19, enzymes which metabolise many clinically used
drugs, have a reduced metabolic capacity which can result
in higher plasma concentrations and increased risk of adverse
e¡ects at ordinary drug dosages, whereas UMs, carrying du-
plicated or multiduplicated genes, do not achieve therapeutic
drug levels. In addition, prodrugs such as proguanil and co-
deine need to be metabolically activated by these enzymes,
and are therefore inactive in PMs.
Cytochrome P450 2A6 (CYP2A6) was ¢rst identi¢ed as the
human coumarin 7-hydroxylase [3,4] and has been shown to
activate a variety of precarcinogens such as 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone, N-nitrosodiethylamine, a£a-
toxin B1, 4,4P-methylene-bis(2-chloroaniline), 1,3-butadiene
and 2,6-dichlorobenzonitrile (see [5^7] and references therein).
In addition, CYP2A6 is involved in the metabolism of certain
pharmaceuticals, such as methoxy£urane [8], halothane [9],
(+)-cis-3,5-dimethyl-2-(3-pyridyl) thiozolidin-4-one hydro-
chloride (SM-12502) [10], losigamone [11], letrozole [12], val-
proic acid [13], and disul¢ram [14]. Nicotine is primarily me-
tabolised to cotinine in humans and this reaction has been
shown to be catalysed mainly by CYP2A6, as well as the
subsequent 3P-hydroxylation of cotinine [15^18].
In vivo phenotyping studies using coumarin as a probe drug
have shown a pronounced interindividual variability in the
expression of CYP2A6 [19^21]. A similar variability has also
been observed when CYP2A6 was measured in human liver
microsomes, with some livers lacking the enzyme [4,22,23].
The explanation is inherent in a polymorphism and three dif-
ferent apparently defective allelic variants of the CYP2A6
gene have been described. CYP2A6*21 encodes an enzyme
with a Leu160CHis substitution, which yields an inactive en-
zyme in a vaccinia virus-based expression system [3]. One
individual was recently reported to be homozygous for this
allele and lacked coumarin 7-hydroxylation capacity in vivo
[25]. The rare CYP2A6*3 allele, generated through a gene
conversion between CYP2A6 and CYP2A7, was also pro-
posed to be inactive [26]. Recently, it has been reported that
some Japanese individuals had a part of the CYP2A6 gene
deleted and subjects homozygous for this allele also exhibited
the PM phenotype [27].
A genotyping method for detection of the CYP2A6*2 and
CYP2A6*3 alleles, based on PCR ampli¢cation combined
with diagnostic restriction enzyme digestion, has been de-
scribed previously [26]. Studies using this method have re-
vealed pronounced interethnic di¡erences in the frequencies
of the CYP2A6 alleles [26,28] and shown that CYP2A6*2 is
the major defective allele in Northern European populations.
However, certain individuals classi¢ed as homozygous for the
CYP2A6*2 allele actually exhibited CYP2A6 activity in vivo
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[26]. This could indicate either that variants of the CYP2A6*2
allele exist which exhibit coumarin 7-hydroxylation activity,
that coumarin is 7-hydroxylated by (an)other enzyme(s) in
these individuals, or that the genotyping method gives an
erroneous classi¢cation with respect to the genotype. We
have investigated the origin of this problem and describe a
new method for detection of the CYP2A6*2 allele which ac-
curately predicts the CYP2A6 phenotype. Using this new
method we found a surprisingly low frequency of this allele
in a random sample of 300 individuals from three di¡erent
European populations.
2. Materials and methods
2.1. Subjects
Phenotype analysis using coumarin combined with genotype anal-
ysis was carried out using a selected cohort of 14 individuals in Fin-
land. Previous phenotype analysis of 100 Finnish patients with newly
diagnosed non-insulin-dependent diabetes mellitus (NIDDM) using
antipyrine, ca¡eine, lidocaine, and coumarin as probe drugs (Rautio
et al., unpublished) revealed two female siblings that were totally
de¢cient in 7-OH-coumarin excretion after oral ingestion of 5 mg
coumarin, who were included in the present study. Phenotype analysis
was also carried out on a group of 11 healthy individuals (eight
women, three men, age range 30^56 years), selected from the sta¡
at the Department of Pharmacology and Toxicology, University of
Oulu. Furthermore, an individual that was shown previously to dis-
play a discrepancy between genotype and phenotype [26], LV 19, was
included. Blood samples were collected into EDTA tubes and genomic
DNA was isolated from Ficoll-enriched leukocytes with a standard
phenol extraction method.
In addition, three di¡erent Caucasian populations of Finnish,
Swedish, and Spanish origin were genotyped to determine the fre-
quency of the CYP2A6*2 allele. Genomic DNA was obtained from
90 randomly sampled volunteers living in the Stockholm area of Swe-
den and 100 volunteers from the Zaragoza area in northern Spain.
These individuals were used previously in CYP2D6 genotype-pheno-
type correlation studies [29,30]. One hundred and forty-four DNA
samples from Finnish volunteers were sampled from the FINRISK’92
study material [31]. The study was approved by the ethical committees
at Karolinska Institutet and the University of Oulu.
2.2. CYP2A6 phenotyping
Following an overnight fast, the subjects voided a urine sample and
ingested a capsule containing 5 mg coumarin and 25 mg rutosides
(Venalot, SchaperpBrummer, Ringelheim, Germany) together with
200 ml of water. Urine was voided 2 h later and 10 ml aliquots of
the urine samples were centrifuged and stored at 320‡C until analysis.
The amount of 7-OH-coumarin in the urine samples was measured by
the HPLC method described by Rautio et al. [19] with minor mod-
i¢cations [32], including treatment of the urine samples with L-glucu-
ronidase and sulphatase to liberate 7-OH-coumarin from conjugates.
The coumarin index refers to the percentage of 7-OH-coumarin ex-
creted from the total 5 mg dose during the 2 h time period.
2.3. Genotyping of the CYP2A6*2 allele
A two-step PCR method was used to detect the CYP2A6*2 allele.
In the ¢rst PCR reaction (PCR I) a part of the CYP2A6 gene was
speci¢cally ampli¢ed and the product was subsequently used as a
template in the second mutation-speci¢c PCR reaction (PCR II).
PCR I was done using primers 2A6ex1 and 2A6ex4R (see Table 1).
The reaction mixture contained approximately 50 ng genomic DNA,
0.25 WM of each primer, 0.2 mM of each dNTP, 1.2 mM MgCl2, 0.6
U of Taq polymerase (Advanced Biotechnologies, Epsom, UK) and
was carried out in 1UReaction Bu¡er IV (Advanced Biotechnologies)
in a total volume of 25 Wl using a Perkin Elmer GeneAmp PCR
System 2400/9600. Initial denaturation was performed at 95‡C for
1 min, followed by 35 cycles each consisting of denaturation at
95‡C for 15 s, annealing at 60‡C for 20 s, and extension at 72‡C
for 3 min, followed by a ¢nal extension at 72‡C for 7 min.
The mixture for the mutation-speci¢c reaction (PCR II) contained
0.8 Wl PCR I product, 0.25 WM of primer 2A6wt or primer 2A6mut,
0.25 WM of primer E3R (see Table 1), 0.1 mM of each dNTP, 1.0 mM
MgCl2, 0.3 U of Taq polymerase, and was done in bu¡er consisting of
10 mM Tris-HCl pH 8.3 and 50 mM KCl in a total volume of 25 Wl.
The ampli¢cation was performed by initial denaturation at 95‡C for
1 min, followed by 16 cycles each involving denaturation at 95‡C for
15 s, annealing at 50‡C for 20 s, and extension at 72‡C for 45 s. PCR
products (12 Wl) were subsequently analysed on a 3% agarose gel
(1.5% agarose, Life Technologies, Rockville, MD, USA plus 1.5%
NuSieve agarose, FMC BioProducts, Vallensbaek Strand, Denmark)
stained with ethidium bromide.
Sample LV 19 was analysed with all four possible combinations of
the forward and reverse primers used for PCR I in the two di¡erent
protocols. The PCR I reaction was carried out using the long PCR
protocol [33] essentially as described by Fernandez-Salguero et al.
[26].
3. Results
3.1. Phenotype analysis
HPLC pro¢les of the urine samples of three individuals are
shown in Fig. 1. The distinct 7-OH-coumarin peak present in
the sample from individual A (LV 31) is lacking in samples
from individuals B (LV 29) and C (LV 26). The 2 h coumarin
test was reproduced several times yielding the same results.
Urine samples were also collected for up to 8 h in these in-
dividuals with no traces of 7-OH-coumarin being detected
during HPLC analysis. The summarised results of the pheno-
types of the 14 Finnish subjects analysed in this study are
presented in Table 2.
3.2. Genotype analysis
The CYP2A6 gene is located on chromosome 19 between
19q12 and 19q13.2 [34], which is adjacent to the CYP2A7
gene that encodes an inactive enzyme product [3,35] and close
to the CYP2A13 gene as well as the two CYP2A7 pseudo-
genes [36]. In our hands, genotype analysis using the original
method described by Fernandez-Salguero et al. [26] (cf. Fig.
2A) often yielded unreliable results usually because of coam-
pli¢cation of the CYP2A7 gene. Furthermore, the previously
phenotyped subject LV 19 had a discrepancy between pheno-
type and apparent genotype, since this subject was classi¢ed as
homozygous for the CYP2A6*2 allele, but clearly exhibited
coumarin 7-hydroxylation activity in vivo [26]. This prompted
us to develop an alternative method for genotype determina-
tion. We designed primers which could speci¢cally amplify a
part of the CYP2A6 gene while avoiding coampli¢cation of
CYP2A13, CYP2A7 and the CYP2A7 pseudogenes. This PCR
fragment was subsequently used as a template for a mutation-
speci¢c PCR reaction as outlined in Fig. 2B.
Table 2 shows the correlation between CYP2A6 genotype
and the coumarin test in the 14 Finnish individuals. The mean
coumarin index of the nine individuals with a CYP2A6*1/*1
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Table 1
Primers used for genotyping of the CYP2A6 gene
Primer Sequence
2A6-ex1 5P-GCT GAA CAC AGA GCA GAT GTA CA-3P
2A6-ex4R 5P-GGA GGT TGA CGT GAA CTG GAA GA-3P
F4a 5P-CCT CCC TTG CTG GCT GTG TCC CAA GCT AGG C-3P
R4a 5P-CGC CCC TTC CTT TCC GCC ATC CTG CCC CCA G-3P
2A6wt 5P-CTC ATC GAC GCC CT-3P
2A6mut 5P-CTC ATC GAC GCC CA-3P
E3Ra 5P-TCG TCC TGG GTG TTT TCC TTC-3P
aFrom Fernandez-Salguero et al. [26].
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genotype was 68% and a lower mean index (54%) was ob-
served for the CYP2A6*1/*2 individuals. The two subjects
described above with no detectable coumarin 7-hydroxylation
activity were both homozygous for the CYP2A6*2 allele (see
Fig. 3). Furthermore, individual LV 19 was clearly determined
to be heterozygous (CYP2A6*1/*2 ; see Fig. 3) which corre-
lates very well with the coumarin index of 40%.
In order to study further the basis for the discrepancy be-
tween the two di¡erent genotyping methods, we ampli¢ed
genomic DNA from individual LV 19 using all of the four
possible combinations of forward primers F4 and ex1 and
reverse primers R4 and ex4R. All four PCR I products were
then subjected to mutation-speci¢c PCR (Fig. 3C). The results
showed that only the CYP2A6*2 and not the CYP2A6*1 al-
lele was ampli¢ed using primer R4 with genomic DNA from
this individual. It is therefore reasonable to assume that many
individuals have mutations at the primer binding site in the 3P
£anking region of the CYP2A6 gene, which would result in no
ampli¢cation of one of the alleles using the primers described
by Fernandez-Salguero et al. [26]. This likely explains the
discrepancy observed previously between phenotype and gen-
otype using this method.
3.3. Allele frequencies of the CYP2A6*2 allele
In order to estimate the prevalence of the CYP2A6*2 allele,
we genotyped more than 300 individuals belonging to three
di¡erent ethnic groups from Europe, namely 90 Swedes, 144
Finns, and 100 individuals from northern Spain (Table 3). No
subject was found to be homozygous for the CYP2A6*2 al-
lele, and the allele frequency was low in all of the populations,
1.1, 1.4 and 3.0% respectively. The observed genotype fre-
quencies did not deviate signi¢cantly from the ones expected
by the Hardy-Weinberg law.
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Table 2
Correlation between the CYP2A6 phenotype and genotype
CYP2A6 genotype Subject Coumarin indexa
CYP2A6*1/*1 LV 1 81
LV 7 70
LV 8 44
LV 11 70
LV 12 84
LV 13 66
LV 15 61
LV 25 72
LV 27 64
Mean: 68
CYP2A6*1/*2 LV 6 73
LV 19 40
LV 37 50
Mean: 54
CYP2A6*2/*2 LV 26 0
LV 29 0
Mean: 0
aPercentage of 7-OH-coumarin excreted from the total 5 mg coumarin
dose during a 2 h period.
Fig. 2. Strategies for CYP2A6 genotyping. A: Schematic representa-
tion of the genotyping method developed by Fernandez-Salguero et
al. [26]. B: Schematic representation of the genotyping method used
in the present study.
Fig. 1. HPLC chromatograms of the 2 h urine samples from poor and extensive metabolisers of coumarin. The arrows show the retention time
of 7-OH-coumarin. A: LV 31; B: LV 29; C: LV 26.
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4. Discussion
Using the genotyping method presented in this report, a
good correlation was obtained between the CYP2A6 genotype
and phenotype and we correctly predicted the phenotype of
the individuals which had previously been misclassi¢ed as
PMs. The mean coumarin index was lower in the three
CYP2A6*1/*2 heterozygotes compared with the CYP2A6*1/
*1 individuals, thereby indicating a gene-dosage e¡ect. Fur-
thermore, we showed that the two individuals homozygous for
the CYP2A6*2 allele displayed no coumarin 7-hydroxylation
activity.
The frequency of the CYP2A6*2 allele determined by this
method was between 1 and 3% in the three European popu-
lations studied. These values are considerably lower than
those previously reported for European populations, namely
4, 15, and 17% in a Spanish, Finnish and English population
respectively [26,28]. An explanation for this di¡erence could
be that individuals were misclassi¢ed in the earlier studies due
to the erroneous method used.
Most genotyping methods using allele-speci¢c PCR amplif-
ication are based on the assumption that the regions where
the PCR primers for the ¢rst PCR reaction bind are conserved
in all of the individuals studied, always resulting in reliable
ampli¢cation. This may of course not always be the case,
especially when the primers bind to sequences in introns and
£anking regions of the genes. We therefore designed the PCR
I primers in exons which are much more conserved between
individuals. The results in Fig. 3C show that ampli¢cation
of the CYP2A6 gene product was also achieved for those
alleles which were not ampli¢ed by the primers used by Fer-
nandez-Salguero et al. [26]. Furthermore, we shortened the
primary ampli¢cation product to 1.8 kb instead of 7.8 kb,
resulting in an easier ampli¢cation and avoiding the smear
problems often seen during prolonged usage of the long-
PCR protocol ([33,37]; I. Johansson, M. Oscarson and
M. Ingelman-Sundberg, unpublished observations). In the
published protocol, the ¢rst PCR product is subjected to an
additional 31 cycles in the exon-speci¢c ampli¢cation [26].
This could be enough for coampli¢cation of CYP2A7 from
genomic DNA carried over from the ¢rst PCR reaction
if the primers used in the second PCR reaction are not specif-
ic for CYP2A6. This would result in erroneous evaluation
of the subsequent diagnostic restriction enzyme digestion,
both with respect to the CYP2A6*2 and CYP2A6*3
alleles.
A reliable genotyping method which accurately predicts the
CYP2A6 phenotype is of interest from a clinical pharmaco-
logical point of view. It is likely that there is a pronounced
variability in the disposition of pharmaceuticals which are
mainly metabolised by CYP2A6, including SM-12502. This
is in analogy with the PM phenotype for CYP2D6 and
CYP2C19, which has been shown to be important for the
interindividual disposition of a number of pharmaceuticals
[38,39]. Furthermore, poor metabolisers may partially be pro-
tected from hepatotoxicity which can result from drugs meta-
bolically activated by CYP2A6 such as valproic acid [13], and
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Fig. 3. CYP2A6 genotyping based on mutation-speci¢c PCR. A:
Ampli¢cation of a part of the CYP2A6 gene from genomic DNA
(‘PCR I’). MW, molecular weight marker V digested with EcoRI/
HindIII (Eastman Kodak Company, New Haven, CT). B: Muta-
tion-speci¢c PCR for detection of the CYP2A6*2 allele (‘PCR II’).
Designation of the samples is the same as for Table 2. MW, 100 bp
DNA ladder (Life Technologies, Rockville, MD). C: PCR II results
obtained from individual LV 19 using four di¡erent combinations
of primers in PCR I.
Table 3
CYP2A6 genotypes and allele frequencies in Swedish, Finnish and Spanish populations
Genotypes (frequency, %) Alleles (frequency, %)
CYP2A6*1/*1 CYP2A6*1/*2 CYP2A6*2/*2 CYP2A6*1 CYP2A6*2
Population
Swedes (n = 90) 97.8 2.2 0.0 98.9 1.1
Finns (n = 144) 97.2 2.8 0.0 98.6 1.4
Spaniards (n = 100) 94.0 6.0 0.0 97.0 3.0
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halothane [9], and possibly from the carcinogenic e¡ects of the
precarcinogens activated by CYP2A6.
As CYP2A6 is responsible for C-oxidation of nicotine,
which is the major metabolic pathway of nicotine [15,40],
Pianezza and co-workers [41] hypothesised that lack of
CYP2A6 would a¡ect smoking behaviour. It was shown
that fewer subjects carrying defective CYP2A6 alleles were
found among smokers as compared to non-smokers and
they also provided evidence that smokers carrying a defective
CYP2A6 allele smoked in general six fewer cigarettes per day.
Because this study used the old genotyping method, it cannot
be excluded that some individuals were misclassi¢ed and that
the conclusions from the study might actually be di¡erent
using a correct protocol.
In conclusion, we have shown the existence of two individ-
uals with a true PM phenotype for CYP2A6 and developed a
new genotyping method for the CYP2A6*2 allele, which well
predicted the CYP2A6 phenotype. These data stress the im-
portance that genotyping methods are validated in large pop-
ulation studies on phenotyped individuals. The present meth-
od can be used in future studies aimed at determining the
prevalence of subjects genetically de¢cient for one CYP2A6
allele among those with chemically induced cancer, experienc-
ing side e¡ects of drugs which are CYP2A6 substrates, or
having various degrees of nicotine dependence.
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